Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547392 | 0.88 | CRBN (0.50) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL27098117 | 0.88 | CRBN (0.50) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL24289157 | 0.85 | CRBN (0.53) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL23594483 | 0.84 | CRBN (0.43) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25469933 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22006673 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23986383 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22906842 | 0.81 | CRBN (0.50) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL29547940 | 0.81 | CRBN (0.50) | CRBNDDB1GSPT1ALDH1A1CHRM2 | |
| SCHEMBL20233810 | 0.81 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | CRBN 871/4885DDB1 1733/4885GSPT1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.